Epigenetic test for risk-stratification impacts gastroenterologists' decision making and improves confidence when caring for patients with Barrett's esophagus. BALTIMORE , Oct. 28, 2024 /PRNewswire/ -- Previse, a gastrointestinal health company, today announced the company presented prospective real-world clinical utility data for Esopredict at the 2024 American College of Gastroenterology Annual Scientific Meeting (ACG) being held October 25-30 in Philadelphia, PA and virtually.
This presentation, awarded for Outstanding Poster Presentation, underscores Previse's commitment to clinicial impact and innovation with Esopredict, the first and only clinically validated and commercially available epigenetic test designed to aid gastroenterologists in optimizing care of patients diagnosed with precancerous Barrett's esophagus. About the poster presentation: Presentation Title: A COMMUNITY-BASED STUDY TO ASSESS A PROGNOSTIC ASSAY'S IMPACT ON GASTROENTEROLOGISTS' BARRETT'S ESOPHAGUS PATIENT SURVEILLANCE AND TREATMENT RECOMMENDATIONS The prospective study evaluates the clinical utility of real-world Esopredict testing in patients with Barrett's esophagus (BE) at multiple gastroenterology centers throughout the United States. Results demonstrate increased intensive surveillance and endoscopic treatment in higher risk patients, reduced surveillance in lower risk patients, and higher confidence in surveillance and treatment decisions.
"The ACG Annual Scientific Meeting provides a premier.